QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in July’s Virtual Investor Summer Spotlight Series

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in the Virtual Investor Summer Spotlight Series. Company CEO John Climaco and chief medical officer Sandra L. Silberman will both be participating on a live webcast … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in July’s Virtual Investor Summer Spotlight Series”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in Upcoming Maxim Group Virtual Healthcare Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in an upcoming webcast fireside chat. The company announced that CEO John Climaco will present at the Healthcare Virtual Conference Part II; the event is presented … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in Upcoming Maxim Group Virtual Healthcare Conference”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Achieves 50%+ Enrollment in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”). The company today announced that its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Achieves 50%+ Enrollment in Potentially Pivotal Berubicin Study”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2023 Results, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended March 31, 2023. In addition, the company provided a clinical update of its anti-cancer drug candidate currently in development for … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2023 Results, Corporate Update”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Board Appointment of Pharma and Biotech Industry Veteran Dr. Bettina M. Cockroft

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its appointment of Bettina M. Cockroft, M.D., M.B.A., to its board of directors. Dr. Cockroft, a well-established industry executive with over 30 years of experience in the … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Board Appointment of Pharma and Biotech Industry Veteran Dr. Bettina M. Cockroft”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Retains Analytics Firm, Investigates Possible Naked Short Selling

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is investigating potential naked short selling of its stock. As part of that process, the company has retained Shareholder Intelligence Services LLC (ShareIntel), a well-known analytics firm. ShareIntel will … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Retains Analytics Firm, Investigates Possible Naked Short Selling”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate, Present at Upcoming Virtual Investor Spotlight Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at an upcoming Virtual Investor Spotlight Event. The event is titled Virtual Investor Spotlight Event – Rapidly Advancing GBM Pivotal Study. According to the announcement, the live, moderated … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate, Present at Upcoming Virtual Investor Spotlight Event”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently reported the enrollment of the first patient in Switzerland as a participant in its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of glioblastoma multiforme (“GBM”). “CNS Pharmaceutical’s adaptive, multicenter, open-label, randomized controlled study targets adult patients with recurrent GBM after failure of standard first-line therapy. In addition, … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Potentially Pivotal Berubicin Trial”

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Global Trial Targets Unmet Medical Need in Arresting GBM Brain Cancer

For decades, medical science has sought an effective means of stopping the most common primary brain cancer in adults in its tracks and keeping it from recurring. In spite of multimodal treatment that includes surgical removal, radiotherapy and chemotherapy, glioblastoma tumors remain the deadliest form of brain cancer and are essentially incurable, leaving patients with … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Global Trial Targets Unmet Medical Need in Arresting GBM Brain Cancer”

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Its Potentially Pivotal Global GBM Trial, Reports No Exposure to SVB Issues

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments, recently reported the enrolment of the first patient in Switzerland as a participant in its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”) (https://ibn.fm/60iyl). An aggressive, fast-growing primary brain tumor, GBM accounts for … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Its Potentially Pivotal Global GBM Trial, Reports No Exposure to SVB Issues”

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered